Department of Endocrinology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China.
Department of Pharmacology (The State‑Province Key Laboratories of Biomedicine‑Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjang 150081, P.R. China.
Mol Med Rep. 2019 Apr;19(4):3190-3200. doi: 10.3892/mmr.2019.9986. Epub 2019 Feb 25.
Hepatic fibrosis is characterized by the aberrant production and deposition of extracellular matrix (ECM) proteins. Growing evidence indicates that the epithelial‑mesenchymal transition serves a crucial role in the progression of liver fibrogenesis. Although a subset of microRNAs (miRNAs or miRs) has recently been identified as essential regulators of the EMT gene expression, studies of the EMT in hyperglycemic‑induced liver fibrosis are limited. In the current study, it was observed that high glucose‑treated AML12 cells occurred EMT process, and miR‑32 expression was markedly increased in the liver tissue of streptozotocin‑induced diabetic rats and in high glucose‑treated AML12 cells. Additionally, the contribution of the EMT to liver fibrosis by targeting metastasis‑associated gene 3 (MTA3) under hyperglycemic conditions was suppressed by AMO‑32. The results indicated that miR‑32 and MTA3 may be considered as novel drug targets in the prevention and treatment of liver fibrosis under hyperglycemic conditions. These finding improves the understanding of the progression of liver fibrogenesis.
肝纤维化的特征是细胞外基质(ECM)蛋白的异常产生和沉积。越来越多的证据表明,上皮-间充质转化在肝纤维化的进展中起着关键作用。尽管最近已经确定了一小部分 microRNAs(miRNAs 或 miRs)作为 EMT 基因表达的重要调节剂,但在高血糖诱导的肝纤维化中对 EMT 的研究是有限的。在本研究中,观察到高葡萄糖处理的 AML12 细胞发生 EMT 过程,并且在链脲佐菌素诱导的糖尿病大鼠的肝组织和高葡萄糖处理的 AML12 细胞中,miR-32 的表达明显增加。此外,在高糖条件下,通过靶向转移相关基因 3(MTA3),EMT 对肝纤维化的贡献被 AMO-32 抑制。结果表明,miR-32 和 MTA3 可被视为预防和治疗高血糖条件下肝纤维化的新型药物靶点。这些发现提高了对肝纤维化进展的认识。